CTIS.eu › Cities › Spain › Sevilla
Sevilla
Spain
1,630 total trials
639 recruiting
Filter these 1,630 trials by phase, condition, sponsor and more.
Open in Search →
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
2024-518008-33-00
5
2025-11-12
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
2024-519345-30-00
5
2025-11-12
IgA nephropathy
2024-519871-24-00
10
2025-11-11
Breast cancer
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
2025-521522-15-00
4
2025-11-05
Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy
2024-516794-70-00
4
2025-11-03
Metastatic non-squamous non-small cell lung cancer
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
2025-520613-31-00
5
2025-10-31
Agitation Associated with Alzheimer’s Disease
2023-509629-36-00
9
2025-10-29
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
2023-503850-11-00
10
2025-10-28
Oligospermia and/or asthenozoospermia
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
2024-514110-12-00
7
2025-10-22
Thyroid Eye Disease
2025-520464-17-00
4
2025-10-21
Atherosclerotic Cardiovascular disease
2024-516924-32-00
5
2025-10-17
Neovascular Age-Related Macular Degeneration (nAMD)
2024-517121-10-00
5
2025-10-17
Menstrual Migraine
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
2025-521838-29-00
3
2025-10-16
Sickle Cell Disease
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
2023-509175-16-00
5
2025-10-14
Sickle cell disease
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
2024-519883-42-00
5
2025-10-08
Non-small cell lung cancer
2025-521147-21-00
4
2025-10-08
Lung Cancer
Showing 385–408 of 1,630 trials